U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06815497) titled 'Telmisartan in Combination with Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer' on Feb. 03.
Brief Summary: The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.
Study Start Date: April 14
Study Type: INTERVENTIONAL
Condition:
Ovarian Cancer
Intervention:
DRUG: Telmisartan
Telmisartan will be introduced as a 40 mg tablet to be taken orally once daily. In participants not experiencing telmisartan dose limiting toxicity, the dose will be escalated to a maximum of 80 mg
Recru...